Rifapentine plus isoniazid weekly probably leads to higher adherence compared with isoniazid daily (moderate certainty).
Rifapentine plus isoniazid weekly probably leads to higher treatment‐limiting adverse events compared with isoniazid daily (moderate certainty).
Rifapentine plus isoniazid weekly leads to lower hepatotoxicity compared with isoniazid daily (high certainty).
Rifampicin probably leads to higher adherence6 compared with isoniazid (moderate certainty).
It is very uncertain whether rifampicin changes treatment‐limiting adverse events compared with isoniazid (very low certainty).
Rifampicin probably leads to lower hepatotoxicity:13 Grade 3 and 4 toxicity compared with isoniazid (moderate certainty).
Rifampicin plus isoniazid showed no clear difference in adherence compared with isoniazid (high certainty).
Rifampicin plus isoniazid showed no clear difference in treatment‐limiting adverse events compared with isoniazid (low certainty).
Rifampicin plus isoniazid showed no clear difference in hepatotoxicity compared with isoniazid (low certainty).